Extranodal NK- and T-cell lymphoma nasal type · 8 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
DeVIC and RT Variant #01 | — | R 26 409 | 63d | — | — | ~1 | ~R 26 409 indirect | — |
SMILE Variant #01 Partial | — | R 11 718 | 21d | — | — | ~6 | ~R 70 309 indirect | — |
GELOX/RT N/A - protocol Partial | — | R 4 925 | 38d | — | — | ~3 | ~R 14 776 indirect | — |
DEP and RT Variant #01 | — | R 1 933 | 38d | — | — | ~2 | ~R 3 865 indirect | — |
MESA/RT N/A - protocol Partial | — | R 1 781 | 21d | — | — | ~4 | ~R 7 124 indirect | — |
LVP Sandwich Variant #01 Partial | — | R 706 | 38d | — | — | ~4 | ~R 2 117 indirect | — |
Cisplatin and RT Variant #01 | — | R 588 | 49d | ~16.6 mo | ~58.6 mo | ~1 | ~R 588 PFS proxy · indirect | 22 |
LVP 'Sandwich' Partial | — | — | — | — | — | — | — | — |
8 of 8 regimens shown